Elixinol Wellness (ELLXF)
OTHER OTC:ELLXF
Want to see ELLXF full AI Analyst Report?
ELLXF Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume25.00
Average Volume (3M)5.17K
Market Cap
$4.43M
Enterprise Value$4.06M
Total Cash (Recent Filing)$1.41M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)―
Beta-3.08
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding413,987,730
10 Day Avg. Volume617
30 Day Avg. Volume5,165
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.15
P/FCF Ratio-0.70
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue0.26
Enterprise Value/Gross Profit1.31
Enterprise Value/Ebitda-0.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Higher‑margin D2C / E‑commerce MixA sustained shift to higher‑margin direct‑to‑consumer sales improves gross margins and cash predictability long term. Digital sales growth (and repeat D2C relationships) reduces dependence on low‑margin wholesale and gives scalable customer economics if acquisition and retention stay efficient.
Structural Cost Reduction And Quarterly ProfitabilityA ~30% structural OpEx cut that produced slightly positive EBITDA and positive underlying cash flow in Q4 materially improves operating leverage. If sustained, the lower fixed cost base makes incremental revenue more profitable and shortens the path to sustained free‑cash‑flow generation.
Vertically Integrated Hemp Platform And Contracted SupplyVertical integration and scale in hemp sourcing reduce input cost volatility and supply risk, supporting margin durability for branded and private‑label lines. Contracted volumes provide a stable production base that supports B2B supply agreements and predictable gross margins over the medium term.
Bears Say
Persistent Negative Operating Cash FlowOngoing negative OCF and FCF mean the business cannot self‑fund growth or working capital and will remain reliant on external financing. Persistent cash burn limits flexibility, raises refinancing risk if markets tighten, and constrains investment in marketing, R&D, or distribution needed to scale revenues.
Balance Sheet Weakening And Rising DebtRising debt and eroding equity reduce financial flexibility and increase leverage risk for a still loss‑making company. Higher indebtedness raises interest and covenant exposure, limits M&A firepower, and may increase funding costs, making execution of growth or turnaround plans harder over the medium term.
Small Absolute Revenue Base And Modest GrowthA small revenue base and only modest full‑year growth limit scale economics and make fixed costs harder to absorb. Limited sales scale increases vulnerability to customer/retailer actions and reduces margin resilience, meaning even modest adverse market moves could materially hurt profitability and cash flow.
Elixinol Wellness News
ELLXF FAQ
What was Elixinol Wellness’s price range in the past 12 months?
Elixinol Wellness lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Elixinol Wellness’s market cap?
Elixinol Wellness’s market cap is $4.43M.
When is Elixinol Wellness’s upcoming earnings report date?
Elixinol Wellness’s upcoming earnings report date is Aug 27, 2026 which is in 96 days.
How were Elixinol Wellness’s earnings last quarter?
Elixinol Wellness released its earnings results on Feb 12, 2026. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.006.
Is Elixinol Wellness overvalued?
According to Wall Street analysts Elixinol Wellness’s price is currently Overvalued.
Does Elixinol Wellness pay dividends?
Elixinol Wellness does not currently pay dividends.
What is Elixinol Wellness’s EPS estimate?
Elixinol Wellness’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elixinol Wellness have?
Elixinol Wellness has 413,987,730 shares outstanding.
What happened to Elixinol Wellness’s price movement after its last earnings report?
Elixinol Wellness reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 50%.
Which hedge fund is a major shareholder of Elixinol Wellness?
Currently, no hedge funds are holding shares in ELLXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elixinol Wellness Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-76.30%
Trailing 12-Months
Asset Growth
-6.80%
Trailing 12-Months
Company Description
Elixinol Wellness
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.
Technical Analysis
Cann Group
―
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―
Ownership Overview
Options Prices
Currently, No data available
---